Stem definition | Drug id | CAS RN |
---|---|---|
antivirals phosphonic acid derivatives | 639 | 113852-37-2 |
Dose | Unit | Route |
---|---|---|
25 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 170 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 90 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.91 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.49 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 26, 1996 | FDA | GILEAD SCIENCES INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adenovirus infection | 263.55 | 62.66 | 48 | 1181 | 3360 | 56287478 |
Drug resistance | 149.82 | 62.66 | 42 | 1187 | 20500 | 56270338 |
BK virus infection | 82.91 | 62.66 | 18 | 1211 | 3046 | 56287792 |
Cytomegalovirus infection reactivation | 82.27 | 62.66 | 18 | 1211 | 3158 | 56287680 |
Cystitis haemorrhagic | 78.42 | 62.66 | 18 | 1211 | 3919 | 56286919 |
Cytomegalovirus infection | 77.75 | 62.66 | 25 | 1204 | 19271 | 56271567 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adenovirus infection | 143.49 | 49.30 | 34 | 1215 | 4720 | 31691375 |
Drug resistance | 116.07 | 49.30 | 41 | 1208 | 23412 | 31672683 |
Cystitis haemorrhagic | 80.90 | 49.30 | 22 | 1227 | 5267 | 31690828 |
Progressive multifocal leukoencephalopathy | 72.99 | 49.30 | 23 | 1226 | 9190 | 31686905 |
Cytomegalovirus infection | 57.35 | 49.30 | 25 | 1224 | 24682 | 31671413 |
Off label use | 52.65 | 49.30 | 66 | 1183 | 347208 | 31348887 |
Drug ineffective for unapproved indication | 51.26 | 49.30 | 21 | 1228 | 17769 | 31678326 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adenovirus infection | 349.49 | 50.46 | 75 | 2356 | 7693 | 70918320 |
Drug resistance | 255.78 | 50.46 | 81 | 2350 | 38109 | 70887904 |
Cystitis haemorrhagic | 142.41 | 50.46 | 37 | 2394 | 8556 | 70917457 |
Cytomegalovirus infection | 124.78 | 50.46 | 48 | 2383 | 39710 | 70886303 |
BK virus infection | 106.66 | 50.46 | 29 | 2402 | 7960 | 70918053 |
Cytomegalovirus infection reactivation | 106.55 | 50.46 | 28 | 2403 | 6753 | 70919260 |
Pathogen resistance | 96.29 | 50.46 | 30 | 2401 | 13249 | 70912764 |
Nephropathy toxic | 94.30 | 50.46 | 32 | 2399 | 18482 | 70907531 |
Epstein-Barr virus infection reactivation | 93.26 | 50.46 | 19 | 2412 | 1497 | 70924516 |
Off label use | 82.45 | 50.46 | 113 | 2318 | 742947 | 70183066 |
Progressive multifocal leukoencephalopathy | 81.59 | 50.46 | 29 | 2402 | 19185 | 70906828 |
Renal impairment | 75.87 | 50.46 | 52 | 2379 | 143885 | 70782128 |
Cytomegalovirus viraemia | 74.75 | 50.46 | 24 | 2407 | 11661 | 70914352 |
Immune reconstitution inflammatory syndrome | 72.25 | 50.46 | 24 | 2407 | 12966 | 70913047 |
Polyomavirus-associated nephropathy | 70.03 | 50.46 | 19 | 2412 | 5164 | 70920849 |
Aplastic anaemia | 55.29 | 50.46 | 21 | 2410 | 16695 | 70909318 |
None
Source | Code | Description |
---|---|---|
ATC | J05AB12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:47868 | photosensitising agent |
CHEBI has role | CHEBI:64946 | anti-AIDS agent |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
CMV Retinitis in AIDS Patients | indication | ||
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients | indication | ||
Prevention of Cytomegalovirus Disease | off-label use | ||
Acidosis | contraindication | 51387008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Severe Chronic Neutropenia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.81 | acidic |
pKa2 | 12.99 | acidic |
pKa3 | 4.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA polymerase catalytic subunit | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4020976 | VUID |
N0000148447 | NUI |
D00273 | KEGG_DRUG |
149394-66-1 | SECONDARY_CAS_RN |
83170 | RXNORM |
4020976 | VANDF |
C0286079 | UMLSCUI |
CHEBI:59495 | CHEBI |
L8P | PDB_CHEM_ID |
CHEMBL152 | ChEMBL_ID |
DB00369 | DRUGBANK_ID |
D000077404 | MESH_DESCRIPTOR_UI |
60613 | PUBCHEM_CID |
JIL713Q00N | UNII |
194597 | MMSL |
4446 | MMSL |
6016 | MMSL |
d04028 | MMSL |
006053 | NDDF |
108688007 | SNOMEDCT_US |
386894007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CIDOFOVIR DIHYDRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-216 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | ANDA | 21 sections |
Vistide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-0101 | INJECTION | 75 mg | INTRAVENOUS | NDA | 24 sections |
CIDOFOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-210 | INJECTION, SOLUTION | 75 mg | INTRAVENOUS | ANDA | 26 sections |